BusinessCeltaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicinesBy Nasdaq OMXFeb 1, 2018, 1:00 PM UTC
BusinessCeltaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory ActivitiesBy Nasdaq OMXJan 4, 2018, 1:02 PM UTC
